A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFR
Not Applicable
- Conditions
- non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000004296
- Lead Sponsor
- Okayama Lung Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Not provided
Exclusion Criteria
1. symptomatic brain metastasis 2. pts with hemoptysis with 2.5mL or more 3. pts with radiological findings of tumor invasion to major vessels (i.e. aorta) and cavity lesion 4. pts with bleeding tendency pts who need continuous use of antithrombotic agents 5. candidate for curative radiation therapy 6. have a history of severe drug allergy 7. woman who is pregnant or wishing to become pregnant 8. pts with massive pleural and cardiac effusion and ascites that need to be immediately treated 9. pts with active co-morbidities including severe conditions of heart diseases, infections, uncontrollable diabetes, uncontollable hypertension, interstitial pneumonia, active hepatitis and thrombotic disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS
- Secondary Outcome Measures
Name Time Method